-
Mashup Score: 46
PURPOSE BRAFV600E mutation is associated with a poor outcome in metastatic colorectal cancer (mCRC). This clinical trial investigated the efficacy of triplet chemotherapy (fluorouracil, folinic acid, oxaliplatin, and irinotecan) combined with either cetuximab or bevacizumab in patients with previously untreated BRAFV600E-mutant mCRC. PATIENTS AND METHODS In this controlled, randomized, open-label phase II trial, 109 patients were randomly assigned, 107 of whom were included into the full analysis set (FAS). Patients were randomly assigned in a 2:1 ratio to receive either FOLFOXIRI plus cetuximab in the experimental arm (n = 72) or FOLFOXIRI plus bevacizumab in the control arm (n = 35). The primary end point was objective response rate (ORR) according to RECIST 1.1., evaluated in patients treated according to protocol (ATP population). Progression-free survival (PFS), overall survival (OS), toxicity, and feasibility were analyzed as secondary end points. RESULTS Eighteen patients discon
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0IDEA Study Prompted Change in Adjuvant Therapy for Colon Cancer - 9 month(s) ago
The IDEA study has influenced the prescribing of adjuvant therapy for patients with stage III colon cancer, researchers found.
Source: www.cancertherapyadvisor.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
An abstract is unavailable.
Source: journals.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Locoregional treatment for colorectal liver metastases aiming for precision medicine - 9 month(s) ago
This review article covers four topics that are important for surgeons to consider as they individualize multidisciplinary treatment for patients with colorectal liver metastases: parenchymal-sparing…
Source: onlinelibrary.wiley.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 1
After delaying his first-ever colonoscopy until age 68, college professor W.F. Strong, Ph.D., now teaches his students about the importance of colonoscopies after his stage III adenocarcinoma diagnosis.
Source: www.mdanderson.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 830-year stage IV colon cancer survivor: Cryoablation clinical trial at MD Anderson saved my life - 9 month(s) ago
Gene Jones was one of the very first people to be treated with cryosurgery, through a clinical trial at MD Anderson. The stage IV colon cancer survivor is still cancer-free today, 30 years later and counting.
Source: www.mdanderson.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Can Rideshares Increase Colonoscopy Screening Rates? - 10 month(s) ago
Study finds it’s a viable solution
Source: huddle.uwmedicine.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1330-year stage IV colon cancer survivor: Cryoablation clinical trial at MD Anderson saved my life - 10 month(s) ago
Gene Jones was one of the very first people to be treated with cryosurgery, through a clinical trial at MD Anderson. The stage IV colon cancer survivor is still cancer-free today, 30 years later and counting.
Source: www.mdanderson.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 830-year stage IV colon cancer survivor: Cryoablation clinical trial at MD Anderson saved my life - 10 month(s) ago
Gene Jones was one of the very first people to be treated with cryosurgery, through a clinical trial at MD Anderson. The stage IV colon cancer survivor is still cancer-free today, 30 years later and counting.
Source: www.mdanderson.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Brisk Walking: No-Cost Option to Improve Cancer Outcomes - 10 month(s) ago
Maurie Markman, MD, discusses a recent paper describing the benefits of walking in patients with stage III colon cancer.
Source: www.medscape.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @ArndtVogel: FOLFOXIRI Plus Cetuximab or Bevacizumab as 1st line Treatment of mBRAFV600E #coloncancer @JCO_ASCO https://t.co/8zZ4tbI8bp…